| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Molecular Targets, and Chemical Biology |
1 Human Genetics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania and 2 Department of Radiation Oncology, Case Comprehensive Cancer Center, Cleveland, Ohio
Requests for reprints: Alfonso Bellacosa, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111. Phone: 215-728-4012; Fax: 215-214-1623; E-mail: Alfonso.Bellacosa{at}fccc.edu.
The base excision repair protein MED1 (also known as MBD4), an interactor with the mismatch repair protein MLH1, has a central role in the maintenance of genomic stability with dual functions in DNA damage response and repair. MED1 acts as a thymine and uracil DNA N-glycosylase on T:G and U:G mismatches that occur at cytosine-phosphate-guanine (CpG) methylation sites due to spontaneous deamination of 5-methylcytosine and cytosine, respectively. To elucidate the mechanisms that underlie sequence discrimination by MED1, we did single-turnover kinetics with the isolated, recombinant glycosylase domain of MED1. Quantification of MED1 substrate hierarchy confirmed MED1 preference for mismatches within a CpG context and showed preference for hemimethylated base mismatches. Furthermore, the kst values obtained with the uracil analogues 5-fluorouracil and 5-iodouracil were over 20- to 30-fold higher than those obtained with uracil, indicating substantially higher affinity for halogenated bases. A 5-iodouracil precursor is the halogenated nucleotide 5-iododeoxyuridine (5IdU), a cytotoxic and radiosensitizing agent. Cultures of mouse embryo fibroblasts (MEF) with different Med1 genotype derived from mice with targeted inactivation of the gene were evaluated for sensitivity to 5IdU. The results revealed that Med1-null MEFs are more sensitive to 5IdU than wild-type MEFs in both 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide and colony formation assays. Furthermore, high-performance liquid chromatography analyses revealed that Med1-null cells exhibit increased levels of 5IdU in their DNA due to increased incorporation or reduced removal. These findings establish MED1 as a bona fide repair activity for the removal of halogenated bases and indicate that MED1 may play a significant role in 5IdU cytotoxicity. (Cancer Res 2006; 66(15): 7686-93)
This article has been cited by other articles:
![]() |
M. I. Ponferrada-Marin, T. Roldan-Arjona, and R. R. Ariza ROS1 5-methylcytosine DNA glycosylase is a slow-turnover catalyst that initiates DNA demethylation in a distributive fashion Nucleic Acids Res., May 13, 2009; (2009) gkp390v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Ishibashi, K. So, C. G. Cupples, and J. Ausio MBD4-Mediated Glycosylase Activity on a Chromatin Template Is Enhanced by Acetylation Mol. Cell. Biol., August 1, 2008; 28(15): 4734 - 4744. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Gurkan, J. E. Schupp, M. A. Aziz, T. J. Kinsella, and K. A. Loparo Probabilistic Modeling of DNA Mismatch Repair Effects on Cell Cycle Dynamics and Iododeoxyuridine-DNA Incorporation Cancer Res., November 15, 2007; 67(22): 10993 - 11000. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. T. Morgan, M. T. Bennett, and A. C. Drohat Excision of 5-Halogenated Uracils by Human Thymine DNA Glycosylase: ROBUST ACTIVITY FOR DNA CONTEXTS OTHER THAN CpG J. Biol. Chem., September 21, 2007; 282(38): 27578 - 27586. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |